A simple to initiate once-daily solution that breaks through the complexity of living with type 2 diabetes
Sanofi India has launched its new diabetes drug Soliqua after having received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) earlier last year. Soliqua is indicated as a treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.
Soliqua offers patients with sustained blood-sugar control, all day, in a simple, once-daily injection that can seamlessly fit into their lifestyle and help them break through the complexity of their diabetes management.
Cyrus Aibara, Head – Diabetes Business Unit, Sanofi (India), “The inclusion of Soliqua to our comprehensive diabetes portfolio (orals and injectables) eases therapy initiation, which helps those prescribed, keep their blood sugar in control more effectively.”
Dr Shalini Menon, Country Medical Lead, Sanofi (India), “In clinical trials, the combination injectable Soliqua has demonstrated effective sugar control, without weight gain and with lower risk of hypoglycemia, compared to twice daily premix insulins.”
Soliqua is a once-daily injectable combination drug containing insulin glargine 100 Units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist. This global innovation is now accessible at a nominal therapy cost of Rs 1850 per pen, enabling wider access to patients living with type II diabetes mellitus.
